1859-49-0

Basic information

• Product Name: BZL-ILE-OH
• Synonyms: BZ-ILE-OH;BZL-ILE-OH;BZL-ISOLEUCINE;BZO-ILE-OH;BENZOYL-L-ISOLEUCINE;BENZYL-L-ISOLEUCINE;N-BENZYL-L-ISOLEUCINE;Benzyl-L-isoleucine≥ 98% (HPLC)
• CAS NO: 1859-49-0
• Molecular Formula: C₁₃H₁₉NO₂
• Molecular Weight: 221.3
• Product Categories: amino acids
• Mol File: 1859-49-0.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Store at RT.
• CAS DataBase Reference: BZL-ILE-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BZL-ILE-OH(1859-49-0)
• EPA Substance Registry System: BZL-ILE-OH(1859-49-0)

Safety Data

• Hazardous Substances Data: 1859-49-0(Hazardous Substances Data)

Usage

Description

BZL-ILE-OH, also known as benzyloxycarbonyl isoleucine, is a chemical compound that serves as a reagent in the synthesis of hydrazinopeptides. It is a white powder with unique chemical properties that allow it to be converted into amino-derivatives using ammonium formate as a catalytic hydrogen transfer agent. This versatile compound has found applications in various fields due to its ability to facilitate the creation of complex peptide structures.

Uses

Used in Pharmaceutical Industry:
BZL-ILE-OH is used as a synthetic reagent for the production of hydrazinopeptides, which are essential in the development of new drugs and therapies. Its role in peptide synthesis is crucial for creating molecules with specific biological activities, making it a valuable component in the pharmaceutical industry.
Used in Chemical Research:
In the field of chemical research, BZL-ILE-OH is used as a starting material for the synthesis of various amino-derivatives. The ability to convert this compound into different forms using ammonium formate as a catalyst allows researchers to explore new chemical pathways and develop novel compounds with potential applications in various industries.
Used in Peptide Synthesis:
BZL-ILE-OH is used as a building block in the synthesis of complex peptides, which are essential for understanding the structure and function of proteins. Its role in peptide synthesis is vital for advancing our knowledge of protein interactions and their roles in biological processes, which can lead to the development of new therapeutic strategies and treatments for various diseases.

Upstream product

• 73-32-5 L-isoleucine 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 658691-27-1 C₁₃H₁₇NO₂ 
• 319-78-8 isoleucine 

Downstream Products

• 1916-91-2 N-Acetoacetyl-N-benzyl-isoleucin 
• 4125-97-7 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanoic acid 
• 66399-70-0 N-benzyl-L-leucine methyl ester 
• 209325-69-9 methyl (2S,3S)-2-(benzylamino)-3-methylpentanoate 
• 188777-47-1 N-benzyl-N-(tert-butoxycarbonylamino)-L-isoleucine 
• 870640-62-3 (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol 
• 870640-63-4 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanal 
• 870640-61-2 (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine 
• 870640-64-5 tert-butyl (3R,4S,5S)-4-[benzyl(methyl)amino]-3-methoxy-5-methyl heptanoate 

Relevant articles and documents

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.